These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 2351867

  • 1. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.
    Arad Y, Ramakrishnan R, Ginsberg HN.
    J Lipid Res; 1990 Apr; 31(4):567-82. PubMed ID: 2351867
    [Abstract] [Full Text] [Related]

  • 2. Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
    Aguilar-Salinas CA, Barrett PH, Kelber J, Delmez J, Schonfeld G.
    J Lipid Res; 1995 Jan; 36(1):188-99. PubMed ID: 7706943
    [Abstract] [Full Text] [Related]

  • 3. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
    Cuchel M, Schaefer EJ, Millar JS, Jones PJ, Dolnikowski GG, Vergani C, Lichtenstein AH.
    Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):1910-7. PubMed ID: 9351353
    [Abstract] [Full Text] [Related]

  • 4. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins.
    Arad Y, Ramakrishnan R, Ginsberg HN.
    Metabolism; 1992 May; 41(5):487-93. PubMed ID: 1588827
    [Abstract] [Full Text] [Related]

  • 5. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
    Forster LF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, Packard CJ, Caslake MJ.
    Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
    [Abstract] [Full Text] [Related]

  • 6. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG.
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [Abstract] [Full Text] [Related]

  • 7. VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100.
    Zulewski H, Ninnis R, Miserez AR, Baumstark MW, Keller U.
    J Lipid Res; 1998 Feb; 39(2):380-7. PubMed ID: 9507998
    [Abstract] [Full Text] [Related]

  • 8. Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss.
    Ginsberg HN, Le NA, Gibson JC.
    J Clin Invest; 1985 Feb; 75(2):614-23. PubMed ID: 3973021
    [Abstract] [Full Text] [Related]

  • 9. Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins.
    Gaw A, Packard CJ, Lindsay GM, Griffin BA, Caslake MJ, Lorimer AR, Shepherd J.
    J Lipid Res; 1995 Jan; 36(1):158-71. PubMed ID: 7706941
    [Abstract] [Full Text] [Related]

  • 10. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK, Lichtenstein AH, Barrett PH, Dolnikowski GG, Schaefer EJ.
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [Abstract] [Full Text] [Related]

  • 11. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D, Griglio S, Le Naour G, Chapman MJ.
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [Abstract] [Full Text] [Related]

  • 12. Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism.
    Vega GL, Grundy SM.
    Kidney Int; 1988 Jun; 33(6):1160-8. PubMed ID: 3165483
    [Abstract] [Full Text] [Related]

  • 13. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [Abstract] [Full Text] [Related]

  • 14. Turnover of 125I-VLDL and 131I-LDL apolipoprotein B in rabbits fed diets containing casein or soy protein.
    Khosla P, Samman S, Carroll KK, Huff MW.
    Biochim Biophys Acta; 1989 Apr 03; 1002(2):157-63. PubMed ID: 2930765
    [Abstract] [Full Text] [Related]

  • 15. Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men.
    Millar JS, Lichtenstein AH, Cuchel M, Dolnikowski GG, Hachey DL, Cohn JS, Schaefer EJ.
    J Lipid Res; 1995 Jun 03; 36(6):1155-67. PubMed ID: 7665994
    [Abstract] [Full Text] [Related]

  • 16. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ.
    Atherosclerosis; 2002 Aug 03; 163(2):287-96. PubMed ID: 12052475
    [Abstract] [Full Text] [Related]

  • 17. Effects of dietary fish oil on serum lipids and VLDL kinetics in hyperlipidemic apolipoprotein E*3-Leiden transgenic mice.
    van Vlijmen BJ, Mensink RP, van 't Hof HB, Offermans RF, Hofker MH, Havekes LM.
    J Lipid Res; 1998 Jun 03; 39(6):1181-8. PubMed ID: 9643349
    [Abstract] [Full Text] [Related]

  • 18. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions.
    Packard CJ, Demant T, Stewart JP, Bedford D, Caslake MJ, Schwertfeger G, Bedynek A, Shepherd J, Seidel D.
    J Lipid Res; 2000 Feb 03; 41(2):305-18. PubMed ID: 10681415
    [Abstract] [Full Text] [Related]

  • 19. Lipoprotein Metabolism in APOB L343V Familial Hypobetalipoproteinemia.
    Hooper AJ, Heeks L, Robertson K, Champain D, Hua J, Song S, Parhofer KG, Barrett PH, van Bockxmeer FM, Burnett JR.
    J Clin Endocrinol Metab; 2015 Nov 03; 100(11):E1484-90. PubMed ID: 26323024
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.
    Arterioscler Thromb Vasc Biol; 1997 Nov 03; 17(11):2589-600. PubMed ID: 9409231
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.